SABR Offers New Hope for Older Patients With Inoperable Kidney Cancer
SAN DIEGO — Stereotactic ablative body radiotherapy (SABR) was an effective, noninvasive strategy for treating primary renal cell carcinoma (RCC) in patients who were not suitable for surgery, according to the FASTRACK II trial. In the prospective, phase II study of 70 patients, none had local progression of kidney cancer during the trial lifetime (median […]
MR-Guided Adaptive SBRT Tied to Reduced Side Effects in Prostate Cancer
Magnetic resonance (MR)‐guided adaptive stereotactic body radiotherapy (SBRT) for prostate cancer was associated with significantly lower rates of acute genitourinary and gastrointestinal toxicities compared with CT-guided non-adaptive SBRT, according to a systematic review and meta-analysis. Across 29 prospective studies involving over 2,500 patients, the risk of short‐term genitourinary side effects was reduced by 44% with […]
MRI-Guided RT Reduced Acute Toxic Effects in Men With Localized Prostate Cancer
Stereotactic body radiotherapy (SBRT) guided by MRI for localized prostate cancer resulted in fewer toxicities and an improvement in quality of life compared with CT guidance, according to the randomized phase III MIRAGE trial. At 3-month follow-up, incidence of acute grade 2 or higher genitourinary toxic effects was 24.4% with MRI-guided SBRT versus 43.4% with […]
Optimizing Treatment for Older Patients With HR+ Low-Risk Breast Cancer
The time has come to revisit the practice of omitting adjuvant radiotherapy (RT) for older patients with early hormone receptor (HR)-positive breast cancer and instead consider a more individualized approach to RT and hormonal therapy, authors of a review article argued. Modern technology and treatment protocols have reduced the toxicity and improved the tolerability of […]
RT After Breast-Conserving Surgery Shows No Survival Advantage Decades Later
Radiotherapy after breast-conserving surgery for early breast cancer substantially reduced the risk of disease recurrence, yet the benefit did not translate to an improvement in overall survival (OS) at 30 years, a long-term analysis of the Scottish breast conservation trial showed. Compared with no radiotherapy, adjuvant locoregional radiotherapy reduced the risk of ipsilateral breast tumor […]
Treatment De-Escalation Shows Promise in Testicular Cancer
A reduced dose of chemotherapy and involved node radiotherapy (INRT) may be viable for patients with stage IIA or IIB seminoma of the testis, results from a phase II study suggested. In a group of 116 patients, a single-dose of carboplatin along with de-escalated INRT yielded a 3-year progression-free survival (PFS) rate of 93.7% (90% […]
SABR for Oligometastatic Cancer Turns in ‘Acceptable’ Rates of Toxicity
Stereotactic ablative radiotherapy (SABR) treatment for oligometastatic or oligoprogressive cancer appeared to come with “acceptable” rates of toxic effects, according to SABR-5 study results. Among a population of 381 patients in the phase II trial, and with a median follow-up of 25 months, rates of grade 2 or greater toxic effects were observed in 18.6%, […]
Long-Term ADT With Radiation Helps Prevent Post-Prostatectomy Metastases
PARIS — In men undergoing radiotherapy after radical prostatectomy, 2 years of androgen deprivation therapy (ADT) improved outcomes when compared with a shorter course of ADT, according to results from the RADICALS-HD trial. At a median follow-up of more than 9 years, investigators found that the longer ADT duration improved metastasis-free survival (MFS) compared with […]
10-Year Follow-Up Confirms Benefit of Chemoradiotherapy in MIBC Patients
Long-term results confirmed that the benefit of adding chemotherapy to radiotherapy was maintained in patients with muscle-invasive bladder cancer (MIBC) in a follow-up to the phase III randomized BC2001 trial. Over a median follow-up of about 10 years, locoregional control was significantly improved by adding 5-fluorouracil and mitomycin C to radiotherapy, with a 5-year recurrence-free […]
Mixed Results With RT Plus Short-Term ADT in Intermediate-Risk Prostate Cancer
CHICAGO — Adding a short course of androgen deprivation therapy (ADT) to dose-escalated radiotherapy (RT) led to a mixed bag of outcomes in intermediate-risk prostate cancer, according to a large randomized trial. The addition of 6 months of ADT did not improve overall survival (OS) compared with RT alone, but the hormonal therapy was associated […]